Login to Your Account



Jazz serving mirv verve: $75M-plus to Immunogen via early stage ADCs deal

By Randy Osborne
Staff Writer

Tuesday, August 29, 2017

Immunogen Inc. has enough cash – almost – to reach the phase III readout with ADC mirvetuximab soravtansine in ovarian cancer, thanks to the option deal for earlier-stage ADCs with Jazz Pharmaceuticals plc, which paid $75 million up front.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription